MediWound director Nachum Shamir acquires 16,336 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MediWound Ltd. director Nachum Shamir exercised Series A Warrants on November 10, 2026, acquiring 16,336 ordinary shares at an exercise price of $13.475 per share and paying the aggregate exercise price in cash. He did not sell the acquired shares; his reported Series A Warrant position after the exercise was zero. The report also lists five direct stock-option positions, including 28,571 underlying ordinary shares at $12.4950 per share, expiring August 17, 2032.
Insider Trade Summary
16,336 shares exercised/converted
Exercise
2 txns
Insider
SHAMIR NACHUM
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Series A Warrants F4 | 16,336 | -- | -- |
| In-the-Money Exercise | Ordinary Shares F4 | 16,336 | $13.475 | $220K |
| Holding | Stock Option (right to buy ordinary shares) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F2, F3 | -- | -- | -- |
| Holding | Ordinary shares F1, F2 | -- | -- | -- |
Holdings After Transaction:
Series A Warrants — 0 warrants (Direct);
Ordinary shares — 73,351 shares (Direct);
Stock Option (right to buy ordinary shares) — 72,141 options (Direct)
Footnotes (4)
- F1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
- F2. There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F3. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
- F4. On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 16,336 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I.
Key Figures
Ordinary shares acquired: 16,336 shares
Warrant exercise price: $13.475 per share
Series A Warrants following exercise: 0 warrants
+5 more
8 metrics
Ordinary shares acquired
16,336 shares
Warrant exercise on November 10, 2026
Warrant exercise price
$13.475 per share
Series A Warrants exercised on November 10, 2026
Series A Warrants following exercise
0 warrants
Reported position following the November 10, 2026 exercise
Underlying ordinary shares under stock option
28,571 shares
Direct option; exercise price $12.4950; expires August 17, 2032
Underlying ordinary shares under stock option
11,800 shares
Direct option; exercise price $11.8850; expires May 30, 2033
Underlying ordinary shares under stock option
12,570 shares
Direct option; exercise price $12.7290; expires February 26, 2034
Underlying ordinary shares under stock option
9,200 shares
Direct option; exercise price $18.5400; expires February 11, 2035
Underlying ordinary shares under stock option
10,000 shares
Direct option; exercise price $17.6000; expires March 4, 2036
Key Terms
Series A Warrants, exercise price, RSUs, vest
4 terms
Series A Warrants financial
"exercised Series A Warrants to purchase 16,336 ordinary shares"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
exercise price financial
"at an exercise price of $13.475 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
RSUs financial
"shares underlying RSUs that were granted"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vest financial
"vest 100% on the one-year anniversary of the grant date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options does MDWD director Nachum Shamir have listed?
Nachum Shamir's listed direct stock-option positions cover 28,571 underlying shares at $12.4950 (expires August 17, 2032), 11,800 at $11.8850 (May 30, 2033), 12,570 at $12.7290 (February 26, 2034), 9,200 at $18.5400 (February 11, 2035), and 10,000 at $17.6000 (March 4, 2036).
AI-generated analysis. How Rhea-AI works. Not financial advice.
